WCG FDAnews
FALLS CHURCH, Va. (PRWEB)
August 31, 2020
Data Integrity in the COVID-19 Era and Beyond
Part II: Key Issues in Data Integrity: Today and Tomorrow
The Second in a Three-Part FDAnews Virtual Conference Series
Wednesday, Sept. 23, 2020, 1:30 p.m. – 5:00 p.m. EDT
https://www.fdanews.com/part2dikeyissues
As the world battles the COVID-19 pandemic, the medical research and manufacturing community is working tirelessly to find solutions. Expectations of the industry to quell the crisis are rising, with the Coronavirus Treatment Acceleration Program, Operation Warp Speed and growing public pressure pushing for effective treatments and vaccines. To answer that need, the FDA has set new guidelines to expedite products that prevent, diagnose or treat the virus.
But this swift pace hasn’t absolved drug and device manufacturers and researchers of their long-held data integrity responsibilities. While the processes may be moving at a quicker pace, these standards remain the steadfast.
What are the best ways to use data to manage a supply chain? How can technological advancements, like AI and blockchain, can improve success? How does a team adjust to this “new normal”?
This three-part FDAnews virtual conference has the answers.
Data integrity expert Sue Schniepp will lead conversations and panels around data in the time of COVID-19. She and a group of experts will share tips and examples around managing suppliers, meeting testing and validation requirements, and dealing with digital transformations around the pandemic. The group will examine what data integrity’s “new normal” may look like and share advice on how organizations can leverage technological developments to meeting changing global needs.
During Part II, we will cover:
● Managing Suppliers
a. Keeping suppliers on track during a global pandemic
b. Using technological developments to secure supply chains
c. Dealing with problematic suppliers
● Measuring Testing and Validation Requirements
a. Ensuring testing and validation meets good manufacturing practices
requirements
b. Taking advantage of technological updates
c. Adapting to the “new normal” after the pandemic
● Dealing with Digital Transformation
a. Making AI and blockchain work for you
b. Complying with electronic submission requirements
c. Preparing for post-pandemic digital obligations
Stay with us for the entire three-part virtual conference and we’ll cover:
● Part I — The Impact of COVID-19: Complying with Data Integrity Guidelines in the Midst of a Pandemic
Purchase as an Encore Presentation. Recorded on Thursday, Aug. 4, 2020
● Part III —The Real-World Costs of Data Integrity
Wednesday, Oct. 28, 2020, 1:30 p.m. – 5:00 p.m.
Don’t let data integrity compliance issues jeopardize the effectiveness, safety, and success of one’s medical products. This virtual conference will provide the tools needed to maintain this crucial element of one’s process, manage a complicated supply chain, and make advances through technological changes.
Interested in registering multiple sites?
Call (888) 838-5578 in the U.S. or +1 (703) 538-7600 globally
to learn about our special multisite discount.
Webinar Details:
Data Integrity in the COVID-19 Era and Beyond
Part II: Key Issues in Data Integrity: Today and Tomorrow
The Second in a Three-Part FDAnews Virtual Conference Series
Wednesday, Sept. 23, 2020, 1:30 p.m. – 5:00 p.m. EDT
https://www.fdanews.com/part2dikeyissues
Tuition:
$287 per site
Easy Ways to Register:
Online: https://www.fdanews.com/part2dikeyissues
By phone: 888.838.5578 or 703.538.7600
About FDAnews:
FDAnews is the premier provider of domestic and international regulatory, legislative, and business news and information for executives in industries regulated by the US FDA and the European Medicines Agency. Pharmaceutical and medical device professionals rely on FDAnews’ print and electronic newsletters, books and conferences to stay in compliance with international standards and the FDA’s complex and ever-changing regulations
Share article on social media or email: